Table 3.
The effect of treatments on GPx, SOD, MDA and TNF-α.
| Parameters | Placebo (n = 20) | BPF (n = 20) | CyC (n = 20) | BPF + CyC (n = 20) |
|---|---|---|---|---|
| GPx (U/mL) | ||||
| Baseline | 195.4 ± 3.6 | 190 .5 ± 4.3 | 192.1 ± 4.6 | 188.1 ± 4.2 |
| Δ16 weeks | 4.7 ± 2.6 | 18.6 ± 2.5 | 19.6 ± 3.8 | 25.9 ± 3.6§ |
| SOD (U/mL) | ||||
| Baseline | 33.7 ± 4.4 | 34.9 ± 4.4 | 35.3 ± 4.9 | 33.3 ± 3.6 |
| Δ16 weeks | 0.16 ± 0.7 | 6.2 ± 1.9 | 7.2 ± 1.3 | 9.8 ± 1.7§ |
| MDA (nmol/mL) | ||||
| Baseline | 4.8 ± 0.4 | 5.1 ± 0.8 | 4.8 ± 0.8 | 4.8 ± 0.6 |
| Δ16 weeks | −0.08 ± 0.05 | −0.9 ± 0.2 | −1.1 ± 0.4 | −1.41 ± 0.3§ |
| TNF-α (pg/mL) | ||||
| Baseline | 95.84 + 8.1 | 94.2 ± 6.8 | 95.3 ± 6.3 | 98.1 + 9.2 |
| Δ16 weeks | −4.6 ± 2.17 | −21 ± 3.1 | −25 ± 7.1 | −28.5 ± 2.2§ |
GPx, glutathione peroxidase; SOD, superoxide dismutase; MDA, malondialdehyde; TNF- tumor necrosis factor alpha; Data are expressed as mean ± SD for each value; §P value of <0.05 between values at 16 week treatment with BPF + CyC compared to placebo group was taken as significant.